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Background and Aim: Carbohydrate deficient transferrin (CDT) is the most specific serum biomarker of heavy
alcohol consumption, defined as ≥ 350–420 g alcohol/week. Despite introduction of a standardized reference
measurement technique, widespread use of CDT remains limited due to low sensitivity. The aim of this study was
to determine the factors that affect diagnostic sensitivity in patients with sustained heavy alcohol intake.
Methods: Patients with a self-reported history of sustained heavy alcohol consumption were recruited from the
hepatology outpatient department or medical wards. Each patient was interviewed with a validated structured
questionnaire of alcohol consumption and CDT analysis using the standardized reference measurement technique
with high performance liquid chromatography was performed on serum collected at time of interview.
Results: 52 patients were recruited: 19 from the hepatology outpatient department and 33 from general medical
wards. Median alcohol intake was 1013 (range 366–5880) g/week over the preceding two week period. 26 patients
had a diagnostic CDT based on a threshold value of %CDT > 1.7 indicating heavy alcohol consumption, yielding a
sensitivity of 50%. Overweight/obesity (defined as body mass index (BMI) ≥ 25 kg/m2 in Caucasians and ≥ 23.0 kg/m2
in Asians), female gender and presence of cirrhosis were independently associated with non-diagnostic %CDT (≤ 1.7).
Conclusions: CDT has limited sensitivity as a biomarker of heavy alcohol consumption. Caution should be applied
when ordering and interpreting %CDT results, particularly in women, patients with cirrhosis and those with an
elevated BMI.
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The relative amount of serum carbohydrate-deficient
transferrin (CDT) is currently the most specific serum
biomarker of heavy alcohol consumption [1]. CDT refers
to a temporary alteration in the glycosylation pattern of
transferrin resulting in an increase in the relative amounts
of disialo- and asialo-transferrin (and a decrease in tetra-
sialotransferrin) that occurs as a result of sustained heavy
alcohol consumption (thresholds range from 50-80 g of
alcohol/day for at least 2 weeks). Altered transferrin glyco-
sylation patterns return to baseline levels within 2 to* Correspondence: e.powell@uq.edu.au
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Using the standardized reference measurement technique
with high performance liquid chromatography (HPLC)
and quantification of disialotransferrin as a percentage
of total transferrin (%CDT), a value of > 1.7 is consid-
ered to be specific for sustained heavy alcohol consump-
tion [3]. Very few circumstances are associated with
“false-positive” %CDT results using HPLC. These include
genetic transferrin variants, [4] rare congenital disorders
of glycosylation [5] and pregnancy [6,7].
In contrast to the high specificity, diagnostic sensitivity
of %CDT for detection of heavy alcohol intake is low.
Previous studies using older methods of CDT analysis such
as immunoassays and anion-exchange methods have iden-
tified several patient characteristics that affect diagnostic
sensitivity [8-13]. These characteristics include gender andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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hypertension and dyslipidemia. We recently examined
the diagnostic utility of %CDT in a hepatology out-
patient setting [14]. Although few patients reported
heavy alcohol consumption at the time of study, those
acknowledged heavy drinkers with a body mass index
(BMI) in the overweight or obese range had significantly
lower %CDT values than lean heavy drinkers [14]. Nei-
ther the presence of compensated chronic liver disease,
nor the etiology of non-alcoholic liver disease influenced
interpretation of the CDT results. A key limitation of
our earlier study and other previous studies investigating
%CDT is the inclusion of patients with a broad range of
alcohol intake and a relatively small proportion of pa-
tients with a heavy alcohol intake, at a level expected
to cause %CDT > 1.7.
Despite recognition that clinical history and self-report
screening tests are efficient methods to identify at-risk
patients, there is clearly a need for an objective bio-
marker to support clinical suspicion of heavy alcohol
intake. In order to improve the clinical utility of CDT
measurements, factors that affect the diagnostic sensitiv-
ity and specificity need to be clearly defined, so that the
test is requested and interpreted appropriately. The aim
of this study was to determine in patients with sustained
heavy alcohol intake, whether the level of %CDT is influ-
enced by BMI or other clinical variables such as gender,
age, ethnicity and smoking. To our knowledge, this is
the first time that these factors have been examined
in a cohort of patients with sustained heavy alcohol
consumption.
Materials and methods
Patients and clinical data
Patients with self-reported heavy alcohol consumption
were recruited from the hepatology outpatient department
or medical wards at the Princess Alexandra Hospital,
Brisbane, Australia during 2012 and 2013. Informed writ-
ten consent was obtained from each patient and the
protocol was approved by Metro-South-Health and the
University of Queensland Human Research Ethics Com-
mittees. Those who agreed to participate were interviewed
by the research co-ordinator using a structured question-
naire and a standard drink guide.
The questionnaire included an alcohol calendar to rec-
ord alcohol consumption over the prior 4-week period and
further direct questions to determine whether the calendar
reflected usual alcohol consumption. It also recorded any
previous periods of heavy alcohol consumption, defined
as ≥ 350 g/week for females and ≥ 420 g/week for males
for ≥ 6 months. These questions were supplemented by val-
idated alcohol screening tools; the Alcohol Use Disorders
Identification Test (AUDIT) [15] and the Brief Michigan
Alcoholism Screening Test (BMAST) [16], to confirmcurrent heavy alcohol consumption (as previously de-
fined) and identify alcohol dependence.
Measurements of weight and height were obtained
from patients at the time of interview. BMI was calcu-
lated as weight in kg/(height in meters)2. BMI was classi-
fied as lean (< 25 kg/m2 in Caucasians, < 23 kg/m2 in Asians),
overweight (25–29.9 kg/m2 in Caucasians, 23.0 to 24.9 kg/m2
in Asians) or obese (≥ 30 kg/m2 in Caucasians, ≥ 25.0 kg/m2
in Asians). Lean body weight (LBW) was calculated using
the Janmahasatian equation, as this has been validated in an
obese population [17], and then used to estimate the volume
of distribution (Vd) of alcohol, since fat has little water.
The medical record was reviewed to ascertain demo-
graphic details, previously diagnosed liver disease and
other medical conditions, medications and history of alco-
hol, tobacco and recreational drug use. Standard biochem-
ical and serological assays, liver imaging and histological
assessment of a liver biopsy (if performed) were used to
assess diagnosis and etiology of liver disease. In the ab-
sence of a liver biopsy, cirrhosis was determined on the
basis of a Fibroscan® result > 14 kPa [18,19] and/or liver
imaging (nodular or irregular liver surface and/or features
of portal hypertension) in conjunction with other clinical
and/or biochemical parameters. The severity of liver dis-
ease was evaluated using the Child-Turcotte-Pugh (CTP)
classification. All patients with chronic hepatitis C had
detection of circulating HCV RNA by polymerase chain
reaction using the Abbott m2000 RealTime System
(Abbott Laboratories, Illinois, USA). Routine haemato-
logical and biochemical tests were performed within 1–3
days of interview and serum collection for CDT analysis.
CDT analysis
Serum was collected at the time of interview and stored
at -80°C, a condition under which the transferrin iso-
form pattern is stable [20]. CDT analysis was performed
on a Waters HPLC System (Waters Corporation Milford
MA USA) as previously described [14]. The currently
accepted laboratory reference value indicative of heavy
drinking is %CDT > 1.7 [3].
Statistical methods
Statistical analyses were performed in SPSS, employing
Fisher’s exact test for categorical variables, either t-test
or Mann–Whitney U-test for continuous variables and
Spearman correlation analysis for univariate tests. Logistic
regression with backward elimination of non-significant
terms was used for multivariate models. A p-value of < 0.05
was considered statistically significant.
Results
Patient characteristics
Overall, 19 patients were recruited from the hepatology
outpatient department and 33 were approached within
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patients reported previous periods of heavy alcohol con-
sumption and excessive alcohol use during the 4 weeks
prior to interview, with a median intake of 1013 (range
366–5880) g/week over the preceding 2 week period. In
the general medicine group, the reason for presentation
was: alcohol intoxication/withdrawal symptoms (n = 21),
alcoholic hepatitis (n = 4), gastrointestinal bleed (n = 3),
infection (n = 4) and pancreatitis (n = 1). Overall, the mean
age of subjects was 50.3 (±11.8) years, 37 (71.2%) were
men and 45 (86.5%) were Caucasian. BMI was lean in 27
patients (51.9%), overweight in 12 (23.1%), and obese in
13 (25%).
Eighteen patients (34.6%) had cirrhosis as determined by
liver biopsy or imaging and 15 patients had evidence of
concurrent hepatitis C infection (HCV). Other chronic
medical conditions included: type 2 diabetes (n = 6), hyper-
tension (n = 20), hyperlipidaemia (n = 9), rheumatoid arth-
ritis (n = 2), COPD/asthma (n = 9), chronic kidney disease
(CKD) > stage 3 (eGFR ≤ 59) (n = 2).
Characteristics of patients with %CDT ≤ or > 1.7
Despite all 52 patients demonstrating heavy drinking based
on results of questionnaires, only 26 had a %CDT > 1.7.
The characteristics of patients with %CDT ≤ or > 1.7 are
detailed in Table 1. A statistically significant difference in
BMI was seen between heavy drinkers with a “diagnostic”
or “non-diagnostic” %CDT. The mean (+/− SD) BMI of
heavy drinkers with %CDT > 1.7 was 23.3 (+/− 3.9) kg/m2,
with 73.1% within the lean weight range. In contrast, the
mean (+/− SD) BMI for heavy drinkers with %CDT ≤ 1.7
was 28.2 (+/− 7.2) kg/m2, with only 30.8% within the lean
weight range. Eighteen of 25 patients (72%) with BMITable 1 Demographic and clinical details of patients in
relation to the %CDT reference cut-off value of 1.7
%CDT ≤ 1.7 %CDT > 1.7 P-value
Subjects (n) 26 26
Caucasian (n, %) 22 (84.6) 23 (88.5) 1.00
Age (years) mean (±SD) 51.1 (±10.2) 49.6 (±13.3) 0.67
Gender (n, % men) 13 (50.0) 24 (92.3) 0.002
BMI (kg/m2) mean (±SD) 28.2 (±7.2) 23.3 (±3.9) 0.003
Smoker (n, %) 14 (53.8) 20 (76.9) 0.14
Median alcohol
consumption last
2 weeks (g/week) (range)




17.3 (6.7–42.2) 24.1 (7.4-82.5) 0.007
AUDIT mean (±SD) 27.6 (±7.2) 28.7 (±6.9) 0.57
BMAST mean (±SD) 17.6 (±8.1) 22.5 (±6.2) 0.018
Cirrhosis (n, %) 15 (57.7) 3 (11.5) 0.001in the overweight/obese range had %CDT ≤ 1.7. The
two overweight/obese patients with notably raised %
CDT had CKD stage 3, with moderately reduced kidney
function (eGFR 30–59). The presence of hypertension did
not differ in relation to %CDT ≤ or > 1.7. Diabetes and
hyperlipidemia were infrequent comorbidities in this
group of patients and therefore their impact could not be
evaluated.
Fifteen of 18 patients (83.3%) with cirrhosis had a non-
diagnostic %CDT. Of these 15 patients, 7 had compen-
sated disease (CTP score A), 7 had functional compromise
(CTP score B) and 1 had decompensated liver disease
(CTP score C). The 3 cirrhotic subjects with %CDT > 1.7
had compensated disease (CTP score A). A statistically
significant difference was also seen between gender and %
CDT category, with women far less likely than men, to
have a diagnostic %CDT. In contrast, ethnicity, age, and
smoking status were comparable between the %CDT
categories.
Median alcohol consumption over the 2 weeks prior
to interview was higher for patients with %CDT > 1.7
(1257.5 g/week) compared to subjects with %CDT ≤ 1.7
(867.5 g/week; p < 0.005). (Table 1) To consider the ef-
fects of body size and composition on alcohol concentra-
tions, alcohol consumption was corrected for apparent
volume of distribution (Vd) of alcohol using estimated
lean body weight (LBW) as a surrogate for Vd. Median al-
cohol consumption per estimated Vd was 17.3 and 24.1g/
week/kg LBW in patients with %CDT ≤ and > 1.7 respect-
ively (P < 0.007). (Table 1) Alcohol consumption (g/wk/kg
LBW) and %CDT were correlated, but the correlation was
better for lean (rs = 0.51, P < 0.01) than overweight sub-
jects (rs = 0.18, P = 0.40), non-cirrhotic (rs = 0.54, P < 0.001)
compared with cirrhotic subjects (rs = 0.02, P = 0.94) and
males (rs = 0.48, P < 0.01) compared with females (rs = 0.15,
P = 0.60) (Figure 1).
Selected laboratory data of patients in relation to
the %CDT reference cut-off value of 1.7 are detailed in
Table 2. No statistically significant differences between the
two groups for laboratory tests commonly used in clinical
practice to suggest sustained heavy alcohol use (serum ami-
notransferases, gamma-glutamyltransferase, platelet count
and mean corpuscular volume) were seen.
Following multivariate analysis initially including age,
gender, cirrhosis, BMI category, alcohol consumption and
smoking status, overweight/obesity (OR = 5.8, p = 0.047),
presence of cirrhosis (OR = 17.2, p = 0.007), female gender
(OR = 14.3, p = 0.019) and lower alcohol consumption
(OR = 0.998, p = 0.029) remained independently associated
with %CDT ≤ 1.7. (Table 3).
Discussion
Although %CDT (determined by the HPLC assay) re-
mains the most specific serum biomarker of prolonged
Figure 1 Correlation of alcohol consumption (g/wk/kg LBW) and
%CDT for: (A) lean vs. overweight/obese subjects; (B) non cirrhotic
vs. cirrhotic subjects; and (C) men vs. women. (#identifies the 2
patients with moderately decreased renal function (eGFR 30–59)).
(LBW= Lean body weight). The vertical line represents 1.7% CDT.
Table 2 Selected laboratory data of patients in relation to







%CDT ≤ 1.7 %CDT >1.7 P-value
Alkaline phosphatase
(U/L)
53-128 101.5 (77.0-161.5) 90.5 (72.8-106.3) 0.16
Gammaglutamyl
transferase (U/L)
< 55 182.0 (110.0-513.3) 135.5 (43.8-283.3) 0.09
Alanine transaminase
(U/L)




< 35 100.0 (49.0-163.5) 76.0 (47.0-139.8) 0.41
Platelets (× 109/L) 140-400 165.5 (94.3-209.3) 168 (130.5-211.5) 0.37
Mean cell
volume (fL)
80-100 98.5 (95.8-101.5) 96.5 (90.8-100.3) 0.16
Table 3 Variables independently associated with a
non-diagnostic %CDT identified by logistic regression
95% Confidence
intervals
Variable Odds ratio Lower Upper P-value
Gender (Women) 14.3 1.5 132.0 0.019
BMI (Overweight/Obese) 5.8 1.0 32.9 0.047
Cirrhosis (Yes) 17.2 2.2 137.0 0.007
Alcohol consumption
over prior 2 weeks (g/week)
0.998 0.996 1.000 0.029
For categorical variables, the odds ratio refers to the category shown in brackets;
for alcohol consumption the odds ratio refers to the decreased likelihood of a
non-diagnostic %CDT per increase in alcohol consumption by 1 g/week.
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clinical practice remains limited, largely due to concern
about poor sensitivity and uncertainty about the factors
that impact on CDT response to alcohol. This study was
undertaken to identify clinical variables that affect the
sensitivity of the standardized HPLC-based CDT assay in
detecting heavy drinkers. Our study shows that only 50%
of subjects drinking >50-60 g alcohol daily for at least
2 weeks had a %CDT > 1.7%, indicative of heavy alcoholintake. Overweight/obesity, the presence of cirrhosis and
female gender were independently associated with a non-
diagnostic %CDT level (≤ 1.7).
Previous population-based studies measuring CDT by
ion-exchange chromatography and immunoassay found
several patient characteristics, including gender, a high
BMI and an insulin-resistant phenotype (high triglycer-
ides and low HDL-cholesterol) were associated with re-
duced sensitivity of the CDT response to alcohol [8,10].
In contrast, more recent studies that quantified CDT
using the standardized HPLC method did not find any
clinically significant differences in CDT in relation to
gender or BMI [21]. The authors concluded that the
earlier findings were related to the analytical techniques
used for measurement of CDT, and that adjustment of ref-
erence intervals in relation to gender or BMI was not re-
quired [3,21]. However, a major limitation of these studies
was the low or unclear number with confirmed heavy
drinking. In our study involving only confirmed heavy
drinkers, elevated BMI and female gender clearly reduce
the diagnostic sensitivity of %CDT using the standardized
HPLC method.
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concentration rather than an absolute value has im-
proved sensitivity and specificity of the assay [22]. Intro-
duction of this method was expected to negate many of
the factors attributed to gender (e.g., pregnancy, oestro-
gens and anaemia), since they can cause variations in
total transferrin concentrations. However, recent reports
using %CDT have demonstrated that gender differences
[23] and pregnancy-related changes in CDT isoform
levels occur, although no biologic mechanism has been
described [7,24]. Women may differ in the CDT iso-
forms that are increased by heavy alcohol intake, such as
asialo- and monosialotransferrin, [25] neither of which are
included in %CDT measurement using the new stan-
dardised HPLC technique. This would be in keeping
with previous findings that women express higher CDT
levels under basal conditions, but produce less in response
to heavy drinking [26,27].
We previously investigated the diagnostic utility of %CDT
in patients with liver disease, and found that heavy
drinkers with a BMI in the overweight or obese range had
significantly lower %CDT values than lean heavy drinkers
[14]. The current study extends these findings by confirm-
ing the results in a larger group of subjects with confirmed
heavy alcohol consumption and by showing that the effect
of BMI is independent of other clinical variables. Inter-
estingly 2 subjects had markedly elevated %CDT values
(9.68% and 12.55%) despite overweight/obesity, in the
setting of moderately decreased renal function (eGFR
30–59). Currently little is known regarding the process
and elimination kinetics of CDT from the circulation and
thus the mechanisms responsible for this effect are
unclear, but may relate to altered elimination in the pres-
ence of renal failure [28]. Chronic kidney disease does
not appear to cause an increase in the baseline levels
of CDT in subjects without hazardous drinking [29]. Simi-
larly, non-enzymatic glycation of transferrin, a process that
may occur in uremia [28] and diabetic subjects [30] does
not appear to interfere with HPLC-based CDT measure-
ment [31].
In our prior study we found that the presence of cir-
rhosis due to various chronic liver diseases did not lead
to “false positive” %CDT results [14]. In the current
study of heavy drinkers, cirrhosis was associated with
reduced sensitivity of the %CDT response to alcohol,
which is contrary to some previous reports [32-34].
This finding confirms earlier studies using non-HPLC
methods that found patients with cirrhosis and a high
current alcohol intake had lower CDT values com-
pared with “control” subjects without liver disease but
drinking more than 50 g alcohol/day [35]. The reasons
underlying these findings remain unclear. Transferrin is
synthesised, glycosylated and secreted by the liver and the
rate of transferrin synthesis is reduced in cirrhotic patients[36]. Furthermore insulin resistance is present in nearly all
patients with cirrhosis [37] and thus similar mechanisms
may reduce the CDT response to alcohol in the setting of
cirrhosis and overweight/obesity.
Conclusions
In conclusion, %CDT has limited sensitivity as an object-
ive biomarker to identify subjects consuming harmful
amounts of alcohol. In our cohort of sustained heavy
drinkers, diagnostic sensitivity of %CDT was 50% and
yielded false negative results in particular patient sub-
groups: women, patients with cirrhosis and those with
an elevated BMI. Therefore caution should be applied
when ordering and interpreting %CDT results in these
subject populations. Further studies with larger numbers
of well-characterised patients, who consume heavy
amounts of alcohol, are required to further assess factors
which impact on the sensitivity of this assay.
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